Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Tbseeg

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07161505Not ApplicableRecruitingPrimary

Personalized Theta-burst Stimulation for Long-lasting Changes in Approach/Avoidance Behavior

NCT05416138Not ApplicableCompletedPrimary

Theta Phase-specific TMS to Modulate Prefrontal Activity

Showing all 2 trials

Research Network

Common Treatments

  • Tbseeg1
  • Tbs Temporal Control1
  • Tbseeg Spatial Control1
  • Transcranial Magnetic Stimulation Tms1
  • Tbseeg Dose Control1

Active Sponsors

  • National Institute of Mental Health (NIMH)2
  • Northwestern University1
  • University of Minnesota1

Top Investigators

Activity Timeline